We have also searched the cBioPortal database which indicates that 6.9% of breast cancer patient xenografts have PAPSS1 amplification and about 2% of lung adenocarcinomas have PAPSS1 mutations. Here, PAPSS1 is linked to lung adenocarcinoma.